The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

Enter: Journavx, the first pain medication of its ... an anesthesiologist and former director of the pain management division at Hospital for Special Surgery in New York. “It appears to be ...

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve clinical outcomes and QOL.

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

It will be sold under the brand name Journavx (JOUR-nah-vix) to treat moderate to severe, acute, short-term pain in adults. It was approved Jan. 30, but is not available for prescription yet.

Earlier this year, Vertex Pharma achieved a milestone with the FDA approval of its NaV1.8 sodium channel inhibitor Journavx (suzetrigine) as a treatment for acute pain management, for example ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid pain management ... its own Nav inhibitor Journavx (suzetrigine) approved ...

If that is a signal of reduced efficacy in chronic pain it could be a drag on Journavx peak sales potential ... Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, UPMC Enterprises ...

Vertex's Journavx launch may boost awareness for ... local analgesic currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...